Clinical comparability of marketed formulations of botulinum toxin

Movement Disorders

Volumn 19, Issue SUPPL. 8, 2004, Pages

  Sampaio, Cristina ^a,b,c   Costa, João ^b,c   Ferreira, Joaquim J ^a,b  

^a Lisbon School of Medicine   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Botulinum toxin; Clinical comparability of formulations; Patent; Potency

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NATURAL PRODUCT; PLACEBO; MUSCLE RELAXANT AGENT;

ADULT; AGED; BIOEQUIVALENCE; BIOLOGICAL WARFARE; BLEPHAROSPASM; CLINICAL TRIAL; COMPETITION; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DYSPHAGIA; DYSTONIA; FEMALE; HEMIFACIAL SPASM; HUMAN; IMMUNOGENICITY; LICENCE; MALE; MEDICAL TECHNOLOGY; MOTOR DYSFUNCTION; NECK MUSCLE; PARESIS; PATENT; PRIORITY JOURNAL; PTOSIS; REVIEW; SEROTYPE; CHEMISTRY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; CHEMISTRY, PHARMACEUTICAL; CONFIDENCE INTERVALS; DYSTONIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; META-ANALYSIS; MIDDLE AGED; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME;

EID: 3242745955     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20066     Document Type: Review

References (43)

1. Kreyden OP. Botulinum toxin: from poison to pharmaceutical the history of a poison that became useful to mankind. 2002;30:94-100.
2. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285: 1059-1070.
3. Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34: 975-995.
4. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) Note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance. CPMP/BWP/3207/00.
5. Quinn N, Hallett M. Dose standardization of botulinum toxin. Lancet 1989;1:964.
6. Pickett AM. Potency equivalence of botulinum toxins preparations. J R Soc Med 1994;87:719.
7. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) Note For Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98.
8. Food Drug administration (FDA). Guidance for Industry Statistical Approaches to Establishing Bioequivalence. Available at: http://www.fda.gov/cder/guidance/3616fnl.htm. Accessed January 2003.
9. Schellekens H, Ryff JC. Biogenerics: the off-patent biotech products. Trends Pharmacol Sci 2002;23:119-121.
10. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59: 102-103.
11. Whurr R, Brookes G, Barnes C. Comparison of dosage effects between the American and British botulinum toxin A product in treatment of spasmodic dysphonia. Mov Disord 1995;10:56.
12. Dressler D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 2000;43:13-16.
13. Wohlfarth K, Bigalke H, Senger M, Goschel H, Dengler R. Effect of dilution on activity of commercial preparations of botulinum toxin type A. Soc Neurosci 1997;23:2234.
14. Bigalke H, Wohlfarth K, Irmer A, Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol 2001; 168:162-170.
15. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355:335-340.
16. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 1995;2:17-18.
17. Marion MH, Sheehy M, Sangla S, et al. Dose standardization of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102-103.
18. Food drug Administration (FDA). BOTOX-Botulinum toxin type A for treatment of cervical dystonia. Clinical review. Online at http://www.fda.gov/cber/review/botaller122100r2p1.pdf. Accessed January 2003.
19. Naumann M, Yakovleff A, Durif F, BOTOX Cervical Dystonia Prospective Study Group. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002; 249:57-63.
20. Ferreira JJ, Costa J, Sampaio C. Botulinum toxin type a for the treatment of cervical dystonia: a systematic review. Eur J Neurol 1999;6(Suppl. 3):76.
21. Costa J, Ferreira JJ, Borges A, Espirito-Santo C, Coelho M, Sampaio C. Botulinum toxin type A therapy for cervical dystonia (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.
22. The Cochrane Library. Available at: http://www.update-software.com/cochrane/. Accessed January 2003.
23. Clarke M, Oxman AD, editors. Cochrane reviewers' handbook 4.1.5 [updated April 2002]. In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. Updated quarterly.
24. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord 1997;12:1013-1018.
25. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
26. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
27. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepbarospasm. Graefes Arch Clin Exp Ophthalmol 1997;235:197-199.
28. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) NeuroBloc. European Public Assessment Report. Online at: http://www.eudra.org/humandocs/Humans/EPAR/neurobloc/neurobloc.htm. Accessed January 2003.
29. Dresseler D. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;73:604.
30. Lu CS, Chen RS, Tsai CH. Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia. J Formos Med Assoc 1995;94:189-192.
31. Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Sjo O, Winkel H. Quantitative EMG in botulinum toxin treatment of cervical dystonia. A double-blind, placebo-controlled study. Electroencephalogr Clin Neurophysiol 1994;93:434-439.
32. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord 1991;6:145-150.
33. Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989;39:80-84.
34. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2: 245-247.
35. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40:1213-1218.
36. Koller W, Vetere-Overfield B, Gray C, Dubinsky R. Failure of fixed-dose, fixed muscle injection of botulinum toxin in torticollis. Clin Neuropharmacol 1990;13:355-358.
37. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
38. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Kunig G. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17.
39. Moore AP, Blumhardt LD. A double blind trial of botulinum toxin "A" in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry 1991;54:813-816.
40. Laubis-HerTmann U, Fries K, Topka H. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study. Eur Neurol 2002;47:214-221.
41. Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, Jech R, Roth J, Brenneis C, Muller J, Schnider P, Auff E, Richardson A, Poewe W. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 2001;248:1073-1078.
42. Annese V, Bassotti G, Coccia G, D'onofrio V, Gatto G, Repici A, Andriulli A. Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group. Aliment Pharmacol Ther 1999; 13:1347-1350.
43. Jefferson T, Demicheli V, Mugford M. Elementary economic evaluation in health care. 2nd ed. London: BMJ Books; 2000.